Key Highlights

  • Apple (NASDAQ:AAPL) climbed 5.31% to a high of USD 349.51 on November 4, 2026, pushing its market Capitalization to roughly USD 5.08 trillion.
  • Amgen (NASDAQ:AMGN) advanced 3.73% to USD 478.48 once it lifted its 2026 Revenue projection, now sitting between USD 38.9 billion and USD 39.7 billion.
  • AerCap (NYSE:AER) raised its full-year adjusted EPS view to around USD 20.70, up from roughly USD 16.80 back in July.
  • Allegion and Andersen Group close out the list at USD 16.25 billion and USD 7.62 billion in market value, and Andersen is purchasing expansion via deals.

1. Apple (NASDAQ:AAPL) Margin Watch

Apple (NASDAQ:AAPL) stands as the biggest company on the all-time-high screen, carrying a Market Value near USD 5.08 trillion following its 5.31% advance to USD 349.51 on November 4, 2026. Roughly 89.6 million shares changed hands, the busiest session since late June. Money left AI hardware over concern about slower data-center spending and rotated toward Apple's leaner capital outlays, and softer oil, lower Treasury yields and expectations of cheaper memory chips also helped. Fiscal fourth-quarter revenue on November 2 reached USD 114.5 billion, a 12% jump, while EPS of USD 2.10 topped the USD 1.99 consensus. The concern sits in the outlook: AAPL projects a December-quarter gross margin between 45% and 46%, down from 47.9% just posted, owing to memory costs. Shares trade near 36 times forward Earnings and carry a screen P/E of 38.94. On November 5 the stock dipped under 2% while the Nasdaq dropped 5.52%.

2. Amgen (NASDAQ:AMGN) Growth Engine

With a market value of USD 258.68 billion, Amgen (NASDAQ:AMGN) climbed 3.73% to USD 478.48 that session, following its third-quarter release on November 3. Sales advanced 8% to USD 10.4 billion, product revenue gained 8% on higher volume, and non-GAAP EPS jumped 14% to USD 6.45. AMGN lifted 2026 revenue projections to a band of USD 38.9 billion to USD 39.7 billion, compared with USD 38.2 billion to USD 39.4 billion previously, and moved its non-GAAP EPS range up to USD 22.90 through USD 23.70. Newer treatments drive expansion: Repatha climbed 37% to USD 1,085 million, EVENITY rose 39% and TEZSPIRE 43%, and UPLIZNA almost tripled. Legacy bone therapies are contracting quickly, Prolia falling 45% and XGEVA 47%. Debt of USD 54.0 billion against USD 13.2 billion in cash is the principal limit on the balance sheet.

3. AerCap (NYSE:AER) Sale-Driven Upgrade

Valued at USD 25.59 billion, AerCap (NYSE:AER) finished at USD 165.72, a 2.04% gain, and carries a screen P/E of only 8.49, the group's lowest. This aircraft lessor posts the biggest guidance raise among the five. Following third-quarter adjusted EPS of USD 6.56, management now projects full-year adjusted EPS near USD 20.70, leaving out fourth-quarter sale gains, versus roughly USD 16.80 in July, an increase of about 23% by our own arithmetic. Deal flow was busy, with 204 transactions made up of 85 leases, 34 purchases and 85 sales. AER repurchased 5.3 million shares for close to USD 783 million as well. Over one year the stock has gained roughly 27.44%. The concern is that earnings lean partly on aircraft sale profits, which are tougher to predict than Lease revenue.

4. Allegion (NYSE:ALLE) Refund-Aided Margin

Allegion (NYSE:ALLE) set a record at USD 192.69, a 1.76% advance, with a market value of USD 16.25 billion. The maker of security products raised third-quarter revenue 9.6% to USD 1,172.6 million, and organic growth reached 7.2%, driven by the Americas at 11.7%. Adjusted EPS climbed 13.0% to USD 2.60, while Operating Margin expanded to 24.3% from 21.8%. Some of that came from Tariff refunds, which contributed USD 19.9 million of operating income, around 1.7% of revenue by our own arithmetic, a boost unlikely to repeat in the same form. ALLE's 2026 outlook calls for adjusted EPS of USD 9.05 to USD 9.10 and reported revenue growth between 9.5% and 10.5%. International looks weaker, with Organic Sales slipping 0.2%. A screen P/E of 23.97 implies the stock already assumes steady growth once the refunds are gone.

5. Andersen Group (NYSE:ANDG) Acquisition Test

Andersen Group (NYSE:ANDG) reached a record USD 67.46 with a 2.71% advance, carrying a market value of USD 7.62 billion, and it will publish third-quarter figures on November 12 once trading ends. Growth has come through purchases. Three acquisitions were completed on November 2, although the names and terms were not gathered, alongside four consulting transactions on October 15. This year it has entered into 19 contracts that add roughly USD 190 million of annualized revenue, close to 19% of the upper bound of its revenue target by our own arithmetic. Projections point to 2026 sales of USD 980 million to USD 1.0 billion, while adjusted EBITDA is expected between USD 225 million and USD 250 million. Second-quarter revenue advanced 23.7% to USD 217.7 million, yet the GAAP outcome was a USD 10.1 million net loss. The screen P/E of 7.88 clashes with those reported losses and is not dependable. At roughly 7.6 times guided sales, ANDG must show on November 12 that the acquisitions are producing profit.

Where Things Stand

On our reading, Amgen has the most solid fundamentals of this group of record-setting giants, pairing 8% revenue expansion with 14% non-GAAP EPS growth and a lifted full-year range, though its USD 54.0 billion of debt weighs most. AerCap posts the largest guidance raise at the cheapest P/E, whereas Apple offers unrivaled size but projects a thinner gross margin next quarter. Allegion's high partly reflects USD 19.9 million of tariff refunds, and Andersen's reflects acquisitions that have yet to translate into profit. Each of the five posted record closes on November 4, 2026, ahead of a wide sell-off, so keeping those levels is the immediate test.